Details
Stereochemistry | ABSOLUTE |
Molecular Formula | C20H24O2 |
Molecular Weight | 296.4034 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 5 / 5 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
C[C@]12CC[C@H]3[C@@H](CCC4=CC(O)=CC=C34)[C@@H]1CC[C@@]2(O)C#C
InChI
InChIKey=BFPYWIDHMRZLRN-SLHNCBLASA-N
InChI=1S/C20H24O2/c1-3-20(22)11-9-18-17-6-4-13-12-14(21)5-7-15(13)16(17)8-10-19(18,20)2/h1,5,7,12,16-18,21-22H,4,6,8-11H2,2H3/t16-,17-,18+,19+,20+/m1/s1
Molecular Formula | C20H24O2 |
Molecular Weight | 296.4034 |
Charge | 0 |
Count |
|
Stereochemistry | ABSOLUTE |
Additional Stereochemistry | No |
Defined Stereocenters | 5 / 5 |
E/Z Centers | 0 |
Optical Activity | UNSPECIFIED |
DescriptionSources: http://www.drugbank.ca/drugs/DB00977Curator's Comment: Description was created based on several sources, including
https://www.drugs.com/dosage/ethinyl-estradiol-levonorgestrel.html
Sources: http://www.drugbank.ca/drugs/DB00977
Curator's Comment: Description was created based on several sources, including
https://www.drugs.com/dosage/ethinyl-estradiol-levonorgestrel.html
Ethinyl estradiol is a synthetic derivative of the natural estrogen estradiol. It is one of two estrogens currently used in oral contraceptive pills. The other, mestranol, is converted to ethinyl estradiol before it is biologically active. Ethinyl estradiol and norethindrone are used together as an oral contraceptive agent. Estrogens diffuse into their target cells and interact with a protein receptor. Target cells include the female reproductive tract, the mammary gland, the hypothalamus, and the pituitary. Estrogens increase the hepatic synthesis of sex hormone binding globulin (SHBG), thyroid-binding globulin (TBG), and other serum proteins and suppress follicle-stimulating hormone (FSH) from the anterior pituitary. This cascade is initiated by initially binding to the estrogen receptors. The combination of an estrogen with a progestin suppresses the hypothalamic-pituitary system, decreasing the secretion of gonadotropin-releasing hormone (GnRH). Used for treatment of moderate to severe vasomotor symptoms associated with the menopause, female hypogonadism, prostatic carcinoma-palliative therapy of advanced disease, breast cancer, as an oral contraceptive, and as emergency contraceptive.
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL206 Sources: http://www.drugbank.ca/drugs/DB00977 |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Preventing | LESSINA-21 Approved UseIndicated for the prevention of pregnancy in women who elect to use oral contraceptives as a method of contraception. Launch Date2002 |
Cmax
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
122.8 pg/mL |
0.06 mg single, oral dose: 0.06 mg route of administration: Oral experiment type: SINGLE co-administered: |
ETHINYL ESTRADIOL plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE food status: FASTED |
AUC
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
1335.8 pg × h/mL |
0.06 mg single, oral dose: 0.06 mg route of administration: Oral experiment type: SINGLE co-administered: |
ETHINYL ESTRADIOL plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE food status: FASTED |
T1/2
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
17.5 h |
0.06 mg single, oral dose: 0.06 mg route of administration: Oral experiment type: SINGLE co-administered: |
ETHINYL ESTRADIOL plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE food status: FASTED |
Doses
Dose | Population | Adverse events |
---|---|---|
5 mg 1 times / day multiple, oral Highest studied dose Dose: 5 mg, 1 times / day Route: oral Route: multiple Dose: 5 mg, 1 times / day Sources: |
healthy, 14-54 |
Other AEs: Vomiting... |
5 mg 1 times / day multiple, oral Highest studied dose Dose: 5 mg, 1 times / day Route: oral Route: multiple Dose: 5 mg, 1 times / day Sources: |
healthy, 14-54 |
Other AEs: Nausea... |
5 mg 1 times / day multiple, oral Highest studied dose Dose: 5 mg, 1 times / day Route: oral Route: multiple Dose: 5 mg, 1 times / day Sources: |
healthy, 14-54 |
Other AEs: Mastalgia... |
0.02 mg 1 times / day multiple, oral Recommended Dose: 0.02 mg, 1 times / day Route: oral Route: multiple Dose: 0.02 mg, 1 times / day Sources: |
healthy, 18-41 Health Status: healthy Age Group: 18-41 Sex: F Sources: |
Disc. AE: Dysfunctional uterine bleeding, Uterine bleeding... AEs leading to discontinuation/dose reduction: Dysfunctional uterine bleeding Sources: Uterine bleeding Headache Mood change Nausea Acne Weight gain |
0.595 mg single, oral Overdose Dose: 0.595 mg Route: oral Route: single Dose: 0.595 mg Sources: |
healthy, 29 |
Disc. AE: Pulmonary embolism... AEs leading to discontinuation/dose reduction: Pulmonary embolism Sources: |
0.02 mg 1 times / day multiple, oral Recommended Dose: 0.02 mg, 1 times / day Route: oral Route: multiple Dose: 0.02 mg, 1 times / day Sources: |
healthy Health Status: healthy Sources: |
Disc. AE: Thromboembolic event, Hepatic disease... AEs leading to discontinuation/dose reduction: Thromboembolic event Sources: Hepatic disease Headache Hypertension Uterine bleeding |
AEs
AE | Significance | Dose | Population |
---|---|---|---|
Vomiting | 23% | 5 mg 1 times / day multiple, oral Highest studied dose Dose: 5 mg, 1 times / day Route: oral Route: multiple Dose: 5 mg, 1 times / day Sources: |
healthy, 14-54 |
Nausea | 48% | 5 mg 1 times / day multiple, oral Highest studied dose Dose: 5 mg, 1 times / day Route: oral Route: multiple Dose: 5 mg, 1 times / day Sources: |
healthy, 14-54 |
Mastalgia | 32% | 5 mg 1 times / day multiple, oral Highest studied dose Dose: 5 mg, 1 times / day Route: oral Route: multiple Dose: 5 mg, 1 times / day Sources: |
healthy, 14-54 |
Acne | Disc. AE | 0.02 mg 1 times / day multiple, oral Recommended Dose: 0.02 mg, 1 times / day Route: oral Route: multiple Dose: 0.02 mg, 1 times / day Sources: |
healthy, 18-41 Health Status: healthy Age Group: 18-41 Sex: F Sources: |
Dysfunctional uterine bleeding | Disc. AE | 0.02 mg 1 times / day multiple, oral Recommended Dose: 0.02 mg, 1 times / day Route: oral Route: multiple Dose: 0.02 mg, 1 times / day Sources: |
healthy, 18-41 Health Status: healthy Age Group: 18-41 Sex: F Sources: |
Headache | Disc. AE | 0.02 mg 1 times / day multiple, oral Recommended Dose: 0.02 mg, 1 times / day Route: oral Route: multiple Dose: 0.02 mg, 1 times / day Sources: |
healthy, 18-41 Health Status: healthy Age Group: 18-41 Sex: F Sources: |
Mood change | Disc. AE | 0.02 mg 1 times / day multiple, oral Recommended Dose: 0.02 mg, 1 times / day Route: oral Route: multiple Dose: 0.02 mg, 1 times / day Sources: |
healthy, 18-41 Health Status: healthy Age Group: 18-41 Sex: F Sources: |
Nausea | Disc. AE | 0.02 mg 1 times / day multiple, oral Recommended Dose: 0.02 mg, 1 times / day Route: oral Route: multiple Dose: 0.02 mg, 1 times / day Sources: |
healthy, 18-41 Health Status: healthy Age Group: 18-41 Sex: F Sources: |
Uterine bleeding | Disc. AE | 0.02 mg 1 times / day multiple, oral Recommended Dose: 0.02 mg, 1 times / day Route: oral Route: multiple Dose: 0.02 mg, 1 times / day Sources: |
healthy, 18-41 Health Status: healthy Age Group: 18-41 Sex: F Sources: |
Weight gain | Disc. AE | 0.02 mg 1 times / day multiple, oral Recommended Dose: 0.02 mg, 1 times / day Route: oral Route: multiple Dose: 0.02 mg, 1 times / day Sources: |
healthy, 18-41 Health Status: healthy Age Group: 18-41 Sex: F Sources: |
Pulmonary embolism | Disc. AE | 0.595 mg single, oral Overdose Dose: 0.595 mg Route: oral Route: single Dose: 0.595 mg Sources: |
healthy, 29 |
Headache | Disc. AE | 0.02 mg 1 times / day multiple, oral Recommended Dose: 0.02 mg, 1 times / day Route: oral Route: multiple Dose: 0.02 mg, 1 times / day Sources: |
healthy Health Status: healthy Sources: |
Hepatic disease | Disc. AE | 0.02 mg 1 times / day multiple, oral Recommended Dose: 0.02 mg, 1 times / day Route: oral Route: multiple Dose: 0.02 mg, 1 times / day Sources: |
healthy Health Status: healthy Sources: |
Hypertension | Disc. AE | 0.02 mg 1 times / day multiple, oral Recommended Dose: 0.02 mg, 1 times / day Route: oral Route: multiple Dose: 0.02 mg, 1 times / day Sources: |
healthy Health Status: healthy Sources: |
Thromboembolic event | Disc. AE | 0.02 mg 1 times / day multiple, oral Recommended Dose: 0.02 mg, 1 times / day Route: oral Route: multiple Dose: 0.02 mg, 1 times / day Sources: |
healthy Health Status: healthy Sources: |
Uterine bleeding | Disc. AE | 0.02 mg 1 times / day multiple, oral Recommended Dose: 0.02 mg, 1 times / day Route: oral Route: multiple Dose: 0.02 mg, 1 times / day Sources: |
healthy Health Status: healthy Sources: |
Overview
CYP3A4 | CYP2C9 | CYP2D6 | hERG |
---|---|---|---|
OverviewOther
Other Inhibitor | Other Substrate | Other Inducer |
---|---|---|
Drug as perpetrator
Target | Modality | Activity | Metabolite | Clinical evidence |
---|---|---|---|---|
Sources: https://pubmed.ncbi.nlm.nih.gov/19454483/ Page: 4.0 |
yes [IC50 1.5 uM] | |||
Sources: https://pubmed.ncbi.nlm.nih.gov/19454483/ Page: 4.0 |
yes [IC50 14 uM] | yes (co-administration study) Comment: No Preincubation; see https://pubmed.ncbi.nlm.nih.gov/17253885/ for list of DDI Sources: https://pubmed.ncbi.nlm.nih.gov/19454483/ Page: 4.0 |
||
Sources: https://pubmed.ncbi.nlm.nih.gov/19454483/ Page: 4.0 |
yes [IC50 15 uM] | |||
Sources: https://pubmed.ncbi.nlm.nih.gov/19454483/ Page: 4.0 |
yes [IC50 19 uM] | yes (co-administration study) Comment: No Preincubation; see https://pubmed.ncbi.nlm.nih.gov/17253885/ for list of DDI Sources: https://pubmed.ncbi.nlm.nih.gov/19454483/ Page: 4.0 |
||
Sources: https://pubmed.ncbi.nlm.nih.gov/19454483/ Page: 4.0 |
yes [IC50 2.1 uM] | |||
Sources: https://pubmed.ncbi.nlm.nih.gov/19454483/ Page: 4.0 |
yes [IC50 2.8 uM] | yes (co-administration study) Comment: No Preincubation; see https://pubmed.ncbi.nlm.nih.gov/17253885/ for list of DDI Sources: https://pubmed.ncbi.nlm.nih.gov/19454483/ Page: 4.0 |
||
Sources: https://pubmed.ncbi.nlm.nih.gov/19454483/ Page: 4.0 |
yes [IC50 24 uM] | |||
Sources: https://pubmed.ncbi.nlm.nih.gov/19454483/ Page: 4.0 |
yes [IC50 3.3 uM] | |||
Sources: https://pubmed.ncbi.nlm.nih.gov/19454483/ Page: 4.0 |
yes [IC50 8.3 uM] | |||
Sources: https://pubmed.ncbi.nlm.nih.gov/19454483/ Page: 4.0 |
yes [IC50 9.2 uM] | |||
Sources: https://pubmed.ncbi.nlm.nih.gov/19454483/ Page: 4.0 |
yes [IC50 9.2 uM] | |||
Sources: https://pubmed.ncbi.nlm.nih.gov/17253885/ Page: 12.0 |
yes | weak (co-administration study) Comment: ~22% increase in clerance of nicotine Sources: https://pubmed.ncbi.nlm.nih.gov/17253885/ Page: 12.0 |
||
Sources: https://pubmed.ncbi.nlm.nih.gov/17253885/ |
yes | yes (co-administration study) Comment: Coadministration with propranolol: ~70% increase in glucuronidation; Coadministration with lamotrigine: ~64% increase in glucuronidation Sources: https://pubmed.ncbi.nlm.nih.gov/17253885/ |
Drug as victim
Target | Modality | Activity | Metabolite | Clinical evidence |
---|---|---|---|---|
major | ||||
major | yes (co-administration study) Comment: see https://pubmed.ncbi.nlm.nih.gov/17253885/ for list of DDI |
|||
minor | ||||
minor | ||||
minor | ||||
yes | ||||
yes | ||||
yes | ||||
yes | yes (co-administration study) Comment: see https://pubmed.ncbi.nlm.nih.gov/17253885/ for list of DDI |
PubMed
Title | Date | PubMed |
---|---|---|
A 1-year pharmacokinetic investigation of a novel oral contraceptive containing drospirenone in healthy female volunteers. | 2000 Dec |
|
Dramatic suppression of plasma and urinary prostate specific antigen and human glandular kallikrein by antiandrogens in male-to-female transsexuals. | 2000 Mar |
|
Ability of xeno- and phytoestrogens to modulate expression of estrogen-sensitive genes in rat uterus: estrogenicity profiles and uterotropic activity. | 2000 May |
|
Low dose of ethinyl estradiol can reverse the antiestrogenic effects of clomiphene citrate on endometrium. | 2001 |
|
Synthetic estrogens-mediated activation of JNK intracellular signaling molecule. | 2001 Apr |
|
Metabolism of chylomicron cholesterol is delayed by estrogen. An in vivo study in the rat. | 2001 Feb |
|
Oral contraceptives in the treatment of acne. | 2001 Feb |
|
Choosing an oestrogen replacement therapy in young adult women with Turner syndrome. | 2001 Feb |
|
Anatomical and histological changes in the oviducts of Japanese quail, Coturnix japonica, after embryonic exposure to ethynyloestradiol. | 2001 Jan |
|
Differential response of immature rat uterine tissue to ethinylestradiol and the red wine constituent resveratrol. | 2001 Jan |
|
Charcoal treatment and risk of escape ovulation in oral contraceptive users. | 2001 Jan |
|
Effects of the synthetic estrogen 17 alpha-ethinylestradiol on the life-cycle of the fathead minnow (Pimephales promelas). | 2001 Jun |
|
Effects of estrogens in vitro and in vivo on cartilage growth in the tilapia (Oreochromis mossambicus). | 2001 Mar |
|
Induction of gene expression in sheepshead minnows (Cyprinodon variegatus) treated with 17beta-estradiol, diethylstilbestrol, or ethinylestradiol: the use of mRNA fingerprints as an indicator of gene regulation. | 2001 Mar |
|
Diane 35 and spironolactone combination in the treatment of hirsutism. | 2001 May |
Sample Use Guides
Usual Adult Dose for Endometriosis
Ethinyl estradiol-levonorgestrel products are packaged in 21 or 28 day dosage preparations. The last seven tablets in 28 day dosage preparations are hormonally inert.
Regardless of the number of tablets in a package, the cycle length for oral contraceptives is generally considered to be 28 days.
Route of Administration:
Oral
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/10837011
EE (=3 uM) completely inhibited TGF-beta-induced apoptosis in cut rat liver slices and hepatocytes
Substance Class |
Chemical
Created
by
admin
on
Edited
Mon Mar 31 17:54:27 GMT 2025
by
admin
on
Mon Mar 31 17:54:27 GMT 2025
|
Record UNII |
423D2T571U
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Common Name | English | ||
|
Preferred Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Brand Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Brand Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Brand Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Brand Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Brand Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Brand Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
WHO-VATC |
QG03AA06
Created by
admin on Mon Mar 31 17:54:27 GMT 2025 , Edited by admin on Mon Mar 31 17:54:27 GMT 2025
|
||
|
NDF-RT |
N0000000100
Created by
admin on Mon Mar 31 17:54:27 GMT 2025 , Edited by admin on Mon Mar 31 17:54:27 GMT 2025
|
||
|
WHO-ESSENTIAL MEDICINES LIST |
18.3.1 (ETH/LEV)
Created by
admin on Mon Mar 31 17:54:27 GMT 2025 , Edited by admin on Mon Mar 31 17:54:27 GMT 2025
|
||
|
WHO-VATC |
QG03AB03
Created by
admin on Mon Mar 31 17:54:27 GMT 2025 , Edited by admin on Mon Mar 31 17:54:27 GMT 2025
|
||
|
WHO-ATC |
G03AA02
Created by
admin on Mon Mar 31 17:54:27 GMT 2025 , Edited by admin on Mon Mar 31 17:54:27 GMT 2025
|
||
|
WHO-ATC |
G03AB05
Created by
admin on Mon Mar 31 17:54:27 GMT 2025 , Edited by admin on Mon Mar 31 17:54:27 GMT 2025
|
||
|
WHO-VATC |
QG03AA07
Created by
admin on Mon Mar 31 17:54:27 GMT 2025 , Edited by admin on Mon Mar 31 17:54:27 GMT 2025
|
||
|
WHO-ATC |
G03AA13
Created by
admin on Mon Mar 31 17:54:27 GMT 2025 , Edited by admin on Mon Mar 31 17:54:27 GMT 2025
|
||
|
WHO-VATC |
QG03AB07
Created by
admin on Mon Mar 31 17:54:27 GMT 2025 , Edited by admin on Mon Mar 31 17:54:27 GMT 2025
|
||
|
WHO-ATC |
G03AA10
Created by
admin on Mon Mar 31 17:54:27 GMT 2025 , Edited by admin on Mon Mar 31 17:54:27 GMT 2025
|
||
|
WHO-ATC |
G03AB01
Created by
admin on Mon Mar 31 17:54:27 GMT 2025 , Edited by admin on Mon Mar 31 17:54:27 GMT 2025
|
||
|
WHO-ATC |
G03CA01
Created by
admin on Mon Mar 31 17:54:27 GMT 2025 , Edited by admin on Mon Mar 31 17:54:27 GMT 2025
|
||
|
WHO-ATC |
G03AA07
Created by
admin on Mon Mar 31 17:54:27 GMT 2025 , Edited by admin on Mon Mar 31 17:54:27 GMT 2025
|
||
|
WHO-VATC |
QL02AA03
Created by
admin on Mon Mar 31 17:54:27 GMT 2025 , Edited by admin on Mon Mar 31 17:54:27 GMT 2025
|
||
|
NDF-RT |
N0000175825
Created by
admin on Mon Mar 31 17:54:27 GMT 2025 , Edited by admin on Mon Mar 31 17:54:27 GMT 2025
|
||
|
WHO-VATC |
QG03AA03
Created by
admin on Mon Mar 31 17:54:27 GMT 2025 , Edited by admin on Mon Mar 31 17:54:27 GMT 2025
|
||
|
WHO-ATC |
G03AA15
Created by
admin on Mon Mar 31 17:54:27 GMT 2025 , Edited by admin on Mon Mar 31 17:54:27 GMT 2025
|
||
|
WHO-VATC |
QG03AA04
Created by
admin on Mon Mar 31 17:54:27 GMT 2025 , Edited by admin on Mon Mar 31 17:54:27 GMT 2025
|
||
|
WHO-ESSENTIAL MEDICINES LIST |
18.3.1 (ETH/NOR)
Created by
admin on Mon Mar 31 17:54:27 GMT 2025 , Edited by admin on Mon Mar 31 17:54:27 GMT 2025
|
||
|
WHO-VATC |
QG03AB01
Created by
admin on Mon Mar 31 17:54:27 GMT 2025 , Edited by admin on Mon Mar 31 17:54:27 GMT 2025
|
||
|
NCI_THESAURUS |
C478
Created by
admin on Mon Mar 31 17:54:27 GMT 2025 , Edited by admin on Mon Mar 31 17:54:27 GMT 2025
|
||
|
WHO-ATC |
G03AA12
Created by
admin on Mon Mar 31 17:54:27 GMT 2025 , Edited by admin on Mon Mar 31 17:54:27 GMT 2025
|
||
|
WHO-ATC |
G03AA16
Created by
admin on Mon Mar 31 17:54:27 GMT 2025 , Edited by admin on Mon Mar 31 17:54:27 GMT 2025
|
||
|
WHO-VATC |
QG03AA12
Created by
admin on Mon Mar 31 17:54:27 GMT 2025 , Edited by admin on Mon Mar 31 17:54:27 GMT 2025
|
||
|
WHO-ATC |
G03AA05
Created by
admin on Mon Mar 31 17:54:27 GMT 2025 , Edited by admin on Mon Mar 31 17:54:27 GMT 2025
|
||
|
WHO-ATC |
G03AA08
Created by
admin on Mon Mar 31 17:54:27 GMT 2025 , Edited by admin on Mon Mar 31 17:54:27 GMT 2025
|
||
|
WHO-ATC |
G03AA04
Created by
admin on Mon Mar 31 17:54:27 GMT 2025 , Edited by admin on Mon Mar 31 17:54:27 GMT 2025
|
||
|
WHO-VATC |
QG03CA01
Created by
admin on Mon Mar 31 17:54:27 GMT 2025 , Edited by admin on Mon Mar 31 17:54:27 GMT 2025
|
||
|
WHO-ATC |
G03AB04
Created by
admin on Mon Mar 31 17:54:27 GMT 2025 , Edited by admin on Mon Mar 31 17:54:27 GMT 2025
|
||
|
WHO-ATC |
G03AB06
Created by
admin on Mon Mar 31 17:54:27 GMT 2025 , Edited by admin on Mon Mar 31 17:54:27 GMT 2025
|
||
|
WHO-VATC |
QG03AA05
Created by
admin on Mon Mar 31 17:54:27 GMT 2025 , Edited by admin on Mon Mar 31 17:54:27 GMT 2025
|
||
|
WHO-VATC |
QG03AA01
Created by
admin on Mon Mar 31 17:54:27 GMT 2025 , Edited by admin on Mon Mar 31 17:54:27 GMT 2025
|
||
|
WHO-VATC |
QG03AA09
Created by
admin on Mon Mar 31 17:54:27 GMT 2025 , Edited by admin on Mon Mar 31 17:54:27 GMT 2025
|
||
|
WHO-ATC |
G03AA06
Created by
admin on Mon Mar 31 17:54:27 GMT 2025 , Edited by admin on Mon Mar 31 17:54:27 GMT 2025
|
||
|
WHO-VATC |
QG03AA10
Created by
admin on Mon Mar 31 17:54:27 GMT 2025 , Edited by admin on Mon Mar 31 17:54:27 GMT 2025
|
||
|
WHO-ATC |
G03AB03
Created by
admin on Mon Mar 31 17:54:27 GMT 2025 , Edited by admin on Mon Mar 31 17:54:27 GMT 2025
|
||
|
WHO-VATC |
QG03AA02
Created by
admin on Mon Mar 31 17:54:27 GMT 2025 , Edited by admin on Mon Mar 31 17:54:27 GMT 2025
|
||
|
FDA ORPHAN DRUG |
28788
Created by
admin on Mon Mar 31 17:54:27 GMT 2025 , Edited by admin on Mon Mar 31 17:54:27 GMT 2025
|
||
|
WHO-VATC |
QG03AA08
Created by
admin on Mon Mar 31 17:54:27 GMT 2025 , Edited by admin on Mon Mar 31 17:54:27 GMT 2025
|
||
|
WHO-VATC |
QG03AB05
Created by
admin on Mon Mar 31 17:54:27 GMT 2025 , Edited by admin on Mon Mar 31 17:54:27 GMT 2025
|
||
|
WHO-ATC |
G03AB07
Created by
admin on Mon Mar 31 17:54:27 GMT 2025 , Edited by admin on Mon Mar 31 17:54:27 GMT 2025
|
||
|
LIVERTOX |
382
Created by
admin on Mon Mar 31 17:54:27 GMT 2025 , Edited by admin on Mon Mar 31 17:54:27 GMT 2025
|
||
|
WHO-VATC |
QG03AB04
Created by
admin on Mon Mar 31 17:54:27 GMT 2025 , Edited by admin on Mon Mar 31 17:54:27 GMT 2025
|
||
|
WHO-ATC |
G03AA11
Created by
admin on Mon Mar 31 17:54:27 GMT 2025 , Edited by admin on Mon Mar 31 17:54:27 GMT 2025
|
||
|
WHO-VATC |
QG03AA13
Created by
admin on Mon Mar 31 17:54:27 GMT 2025 , Edited by admin on Mon Mar 31 17:54:27 GMT 2025
|
||
|
WHO-VATC |
QG03AA16
Created by
admin on Mon Mar 31 17:54:27 GMT 2025 , Edited by admin on Mon Mar 31 17:54:27 GMT 2025
|
||
|
WHO-VATC |
QG03AA15
Created by
admin on Mon Mar 31 17:54:27 GMT 2025 , Edited by admin on Mon Mar 31 17:54:27 GMT 2025
|
||
|
WHO-ATC |
G03AA03
Created by
admin on Mon Mar 31 17:54:27 GMT 2025 , Edited by admin on Mon Mar 31 17:54:27 GMT 2025
|
||
|
WHO-ATC |
G03AA09
Created by
admin on Mon Mar 31 17:54:27 GMT 2025 , Edited by admin on Mon Mar 31 17:54:27 GMT 2025
|
||
|
WHO-VATC |
QG03AB02
Created by
admin on Mon Mar 31 17:54:27 GMT 2025 , Edited by admin on Mon Mar 31 17:54:27 GMT 2025
|
||
|
WHO-ATC |
G03AA01
Created by
admin on Mon Mar 31 17:54:27 GMT 2025 , Edited by admin on Mon Mar 31 17:54:27 GMT 2025
|
||
|
WHO-VATC |
QG03AB06
Created by
admin on Mon Mar 31 17:54:27 GMT 2025 , Edited by admin on Mon Mar 31 17:54:27 GMT 2025
|
||
|
EMA ASSESSMENT REPORTS |
EVRA (AUTHORIZED: CONTRACEPTION)
Created by
admin on Mon Mar 31 17:54:27 GMT 2025 , Edited by admin on Mon Mar 31 17:54:27 GMT 2025
|
||
|
WHO-VATC |
QG03AA11
Created by
admin on Mon Mar 31 17:54:27 GMT 2025 , Edited by admin on Mon Mar 31 17:54:27 GMT 2025
|
||
|
WHO-ATC |
G03AB02
Created by
admin on Mon Mar 31 17:54:27 GMT 2025 , Edited by admin on Mon Mar 31 17:54:27 GMT 2025
|
||
|
WHO-ATC |
L02AA03
Created by
admin on Mon Mar 31 17:54:27 GMT 2025 , Edited by admin on Mon Mar 31 17:54:27 GMT 2025
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
SUB07277MIG
Created by
admin on Mon Mar 31 17:54:27 GMT 2025 , Edited by admin on Mon Mar 31 17:54:27 GMT 2025
|
PRIMARY | |||
|
423D2T571U
Created by
admin on Mon Mar 31 17:54:27 GMT 2025 , Edited by admin on Mon Mar 31 17:54:27 GMT 2025
|
PRIMARY | |||
|
423D2T571U
Created by
admin on Mon Mar 31 17:54:27 GMT 2025 , Edited by admin on Mon Mar 31 17:54:27 GMT 2025
|
PRIMARY | |||
|
5991
Created by
admin on Mon Mar 31 17:54:27 GMT 2025 , Edited by admin on Mon Mar 31 17:54:27 GMT 2025
|
PRIMARY | |||
|
1260001
Created by
admin on Mon Mar 31 17:54:27 GMT 2025 , Edited by admin on Mon Mar 31 17:54:27 GMT 2025
|
PRIMARY | |||
|
C486
Created by
admin on Mon Mar 31 17:54:27 GMT 2025 , Edited by admin on Mon Mar 31 17:54:27 GMT 2025
|
PRIMARY | |||
|
ETHINYL ESTRADIOL
Created by
admin on Mon Mar 31 17:54:27 GMT 2025 , Edited by admin on Mon Mar 31 17:54:27 GMT 2025
|
PRIMARY | Description: A white to slightly yellowish white, crystalline powder; odourless.Solubility: Practically insoluble in water; freely soluble in ethanol (~750 g/l) TS; soluble in acetone R and dioxan R.Category: Estrogen.Storage: Ethinylestradiol should be kept in a well-closed container, protected from light.Additional information: Ethinylestradiol may exist in 2 polymorphic forms one of which melts at about 183?C, the other, metastable, at about 143?C.RequirementsDefinition: Ethinylestradiol contains not less than 97.0% and not more than 102.0% of C20H24O2, calculated with reference to the dried substance. | ||
|
4903
Created by
admin on Mon Mar 31 17:54:27 GMT 2025 , Edited by admin on Mon Mar 31 17:54:27 GMT 2025
|
PRIMARY | |||
|
10973
Created by
admin on Mon Mar 31 17:54:27 GMT 2025 , Edited by admin on Mon Mar 31 17:54:27 GMT 2025
|
PRIMARY | |||
|
100000091721
Created by
admin on Mon Mar 31 17:54:27 GMT 2025 , Edited by admin on Mon Mar 31 17:54:27 GMT 2025
|
PRIMARY | |||
|
CHEMBL691
Created by
admin on Mon Mar 31 17:54:27 GMT 2025 , Edited by admin on Mon Mar 31 17:54:27 GMT 2025
|
PRIMARY | |||
|
DB00977
Created by
admin on Mon Mar 31 17:54:27 GMT 2025 , Edited by admin on Mon Mar 31 17:54:27 GMT 2025
|
PRIMARY | |||
|
m5058
Created by
admin on Mon Mar 31 17:54:27 GMT 2025 , Edited by admin on Mon Mar 31 17:54:27 GMT 2025
|
PRIMARY | Merck Index | ||
|
D004997
Created by
admin on Mon Mar 31 17:54:27 GMT 2025 , Edited by admin on Mon Mar 31 17:54:27 GMT 2025
|
PRIMARY | |||
|
Ethinyl Estradiol
Created by
admin on Mon Mar 31 17:54:27 GMT 2025 , Edited by admin on Mon Mar 31 17:54:27 GMT 2025
|
PRIMARY | |||
|
DTXSID5020576
Created by
admin on Mon Mar 31 17:54:27 GMT 2025 , Edited by admin on Mon Mar 31 17:54:27 GMT 2025
|
PRIMARY | |||
|
200-342-2
Created by
admin on Mon Mar 31 17:54:27 GMT 2025 , Edited by admin on Mon Mar 31 17:54:27 GMT 2025
|
PRIMARY | |||
|
4124
Created by
admin on Mon Mar 31 17:54:27 GMT 2025 , Edited by admin on Mon Mar 31 17:54:27 GMT 2025
|
PRIMARY | RxNorm | ||
|
437
Created by
admin on Mon Mar 31 17:54:27 GMT 2025 , Edited by admin on Mon Mar 31 17:54:27 GMT 2025
|
PRIMARY | |||
|
7071
Created by
admin on Mon Mar 31 17:54:27 GMT 2025 , Edited by admin on Mon Mar 31 17:54:27 GMT 2025
|
PRIMARY | |||
|
1082
Created by
admin on Mon Mar 31 17:54:27 GMT 2025 , Edited by admin on Mon Mar 31 17:54:27 GMT 2025
|
PRIMARY | |||
|
57-63-6
Created by
admin on Mon Mar 31 17:54:27 GMT 2025 , Edited by admin on Mon Mar 31 17:54:27 GMT 2025
|
PRIMARY | |||
|
3587
Created by
admin on Mon Mar 31 17:54:27 GMT 2025 , Edited by admin on Mon Mar 31 17:54:27 GMT 2025
|
PRIMARY | |||
|
ETHINYL ESTRADIOL
Created by
admin on Mon Mar 31 17:54:27 GMT 2025 , Edited by admin on Mon Mar 31 17:54:27 GMT 2025
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
BASIS OF STRENGTH->SUBSTANCE |
ASSAY (HPLC)
USP
|
||
|
METABOLIC ENZYME -> SUBSTRATE |
MAJOR
|
||
|
METABOLIC ENZYME -> INHIBITOR |
IC50
|
||
|
METABOLIC ENZYME -> SUBSTRATE | |||
|
DERIVATIVE -> PARENT |
|
||
|
METABOLIC ENZYME -> SUBSTRATE |
MAJOR
|
||
|
BASIS OF STRENGTH->SUBSTANCE |
ASSAY (HPLC)
EP
|
||
|
METABOLIC ENZYME -> SUBSTRATE | |||
|
METABOLIC ENZYME -> SUBSTRATE |
Related Record | Type | Details | ||
---|---|---|---|---|
|
METABOLITE -> PARENT |
MAJOR
URINE
|
||
|
METABOLITE -> PARENT |
|
||
|
METABOLITE -> PARENT |
|
||
|
METABOLITE -> PARENT |
MAJOR
PLASMA
|
||
|
PRODRUG -> METABOLITE ACTIVE |
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
IMPURITY -> PARENT |
For the calculation of contents, multiply the peak areas by 0.7
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
IMPURITY -> PARENT |
For the calculation of contents, multiply the peak areas by 0.4
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |
|